Simulation of antibiotic pharmacodynamic exposure for the empiric treatment of nosocomial bloodstream infections: A report from the OPTAMA program

Clinical Therapeutics

Volumn 27, Issue 7, 2005, Pages 1032-1042

  Maglio, Dana ^a   Kuti, Joseph L ^a   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

Bloodstream infections; Cefepime; Ceftazidime; Ciprofloxacin; Imipenem; Meropenem; Pharmacodynamics; Pharmacokinetics; Piperacillin tazobactam

Indexed keywords

CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERICIDAL ACTIVITY; COMPUTER MODEL; DISEASE SIMULATION; DOSE CALCULATION; DRUG DOSE REGIMEN; DRUG MONITORING; DRUG SURVEILLANCE PROGRAM; GRAM NEGATIVE SEPSIS; HOSPITAL INFECTION; INFECTION RATE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD;

ANTI-BACTERIAL AGENTS; BACTEREMIA; CROSS INFECTION; HUMANS; LIKELIHOOD FUNCTIONS; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; MONTE CARLO METHOD; STAPHYLOCOCCUS AUREUS;

EID: 24344471255     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2005.07.004     Document Type: Article

References (42)

1. Pittet D, Tarara D, and Wenzel RP Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs, and attributable mortality JAMA. 271 1994 1598 1601
2. Karchmer AW Nosocomial bloodstream infections: Organ isms,risk factors, and implications Clin Infect Dis. 31 Suppl 4 2000 S139 S143
3. Bodey GP, Jadeja L, and Elting L Pseudomonas bacteremia. Retrospective analysis of 410 episodes Arch Intern Med. 145 1985 1621 1629
4. Weinstein MP, Towns ML, and Quartey SM The clinical significance of positive blood cultures in the 1990s: A prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults Clin Infect Dis. 24 1997 584 602
5. Ibrahim EH, Sherman G, and Ward S The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting Chest. 118 2000 146 155
6. Kang CI, Kim SH, and Kim HB Pseudomonas aeruginosa bacteremia: Risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome Clin Infect Dis. 37 2003 745 751
7. Kollef MH Inadequate antimicrobial treatment: An important determinant of outcome for hospitalized patients Clin Infect Dis. 31 Suppl 4 2000 S131 S138
8. Biedenbach DJ, Moet GJ, and Jones RN Occurrence and an timicrobial resistance pattern comparisons among blood-stream infection isolates from the SENTRY antimicrobial surveillance program (1997-2002) Diag Microbiol Infect Dis. 50 2004 59 69
9. NNIS System National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003 Am J Infect Control. 31 2003 481 498
10. Neuhauser MM, Weinstein RA, and Rydman R Antibiotic resistance among gram-negative bacilli in US intensive care units: Implications for fluoroquinolones use JAMA. 289 2003 885 888
11. Rhomberg PR, Jones RN for the MYSTIC Program (USA) Study Group Antimicrobial spectrum of activity for meropenem and nine broad spectrum antimicrobials: Report from the MYSTIC Program (2002) in North America Diagn Microbiol Infect Dis. 47 2003 365 372
12. Jones RN, and Masterton R Determining the value of antimi crobial surveillance programs Diagn Microbiol Infect Dis. 41 2001 171 175
13. Gillespie EL, Kuti JL, and Nicolau DP When 'S' doesn't mean success: The importance of choice of antibiotic and dose on clinical and economic outcomes of severe infection Conn Med. 69 2005 203 210
14. Craig WA Pharmacokinetic/pharmacodynamic parameters: Rationale for antibiotic dosing of mice and men Clin Infect Dis. 26 1998 1 10
15. Moore RD, Lietman PS, and Smith CR Clinical response to aminoglycoside therapy: Importance of the ratio of peak concentration to minimal inhibitory concentration J Infect Dis. 155 1987 93 99
16. Forrest A, Nix DE, and Ballow CH Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients Antimicrob Agents Chemother. 37 1993 1073 1081
17. Turnidge JD The pharmacodynamics of beta-lactams Clin Infect Dis. 27 1998 10 22
18. Kuti JL, Nightingale CH, and Nicolau DP Optimizing pharmacodynamic target attainment using the MYSTIC antibiogram: Data collected in North America in 2002 Antimicrob Agents Chemother. 48 2004 2464 2470
19. Kiffer CR, Mendes C, Kuti JL, and Nicolau DP Pharmacodynamic comparisons of antimicrobials against noso comial isolates of Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa from the MYSTIC surveillance program: The OPTAMA Program, SouthAmerica 2002 Diagn Microbiol Infect Dis. 49 2004 109 116
20. Masterton RG, Kuti JL, Turner PJ, and Nicolau DP The OPTAMA programme: Utilizing MYSTIC (2002) to predict critical pharmacodynamic target attainment against nosocomial pathogens in Europe J Antimicrob Chemother. 55 2005 71 77
21. Jones RN, Rubino CM, Bhavnani SM for the Antimicrobial Resistance Rate Epidemiology Study Team Program Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae: Report from the Antimicrobial Resistance Rate Epidemiology Study Team Antimicrob Agents Chemother. 47 2003 292 296
22. Ambrose PG, Bhavnani SM, and Jones RN Pharmacokinetics-pharmacodynamics of cefepime and piperacillin/tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum beta lactamases: Report from the ARREST program Antimicrob Agents Chemother. 47 2003 1643 1646
23. Dreetz M, Hamacher J, and Eller J Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenemcilastatin Antimicrob Agents Chemother. 40 1996 105 109
24. Klepser ME, Patel KP, and Nicolau DP Comparison of the bactericidal activities of ofloxacin and ciprofloxacin alone and in combination with ceftazidime and piperacillin against clinical strains of Pseudomonas aeruginosa Antimicrob Agents Chemother. 39 1995 2503 2510
25. Mouton JW, Horrevorts AM, and Mulder PG Pharmacokinetics of ceftazidime in serum and suction blister fluidduring continuous and intermittent infusion in healthy volunteers Antimicrob Agents Chemother. 34 1990 2307 2311
26. Nye KJ, Shi YG, Andrew JM, and Wise R Pharmacokinetics and tissue penetration of cefepime J Antimicrob Chemother. 24 1989 23 28
27. Occhipinti DJ, Pendland SL, and Schoonover LL Pharmacokinetics and pharmacodynamics of two multiple-dose piperacillintazobactam regimens Antimicrob Agents Chemother. 41 1997 2511 2517
28. Rhomberg PR, Jones RN, Sader HS, Fritsche TR for the MYSTIC Programme Study Group Antimicrobial resistance ratesand clonality results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) programme: Report of year five (2003) Diagn Microbiol Infect Dis. 49 2004 273 281
29. Performance Standards for Antimicrobial Susceptibility Testing 2002 National Committee for Clinical Laboratory Standards Wayne, Pa
30. [published correction appears in Clin Infect Dis. 2004; 39:1093] Wisplinghoff H, Bischoff T, and Tallent SM Nosocomial bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study Clin Infect Dis. 39 2004 309 317
31. Reynolds R, Potz N, and Colman M for the BSAC Extended Working Party on Bacteraemia Resistance Surveillance Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001-2002: The BSAC Bacteraemia Resistance Surveillance Programme J Antimicrob Chemother. 53 2004 1018 1032
32. Abstract A-138 Ambrose PG, Bhavnani SM, and Jones RN Use of pharmacokinetics-pharmacodynamics and Monte Carlo simulation as decision support for the reevaluation of NCCLS cephem susceptibility breakpoints for Enterobacteriaceae Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy 2004 American Society for Microbiology Washington, DC
33. Bradley JS, Dudley MN, and Drusano GL Predicting efficacy of antiinfectives with pharmacodynamics and Monte Carlo simulation Pediatr Infect Dis J. 22 2003 982 992
34. Karlowsky JA, Jones ME, and Thornsberry C Trends in antimicrobial susceptibilities among Enterobacteriaceae isolated from hospitalized patients in the United States from 1998 to 2001 Antimicrob Agents Chemother. 47 2003 1672 1680
35. Mermel LA, Farr BM, Sherertz RJ for the Infectious Diseases Society of America, American College of Critical Care Medicine, and Society of Healthcare Epidemiology of America Guidelines for the management of intravascular catheter-related infections Clin Infect Dis. 32 2001 1249 1272
36. Abstract A-1867 Ong CT, Tessier PR, and Li C Efflux pumps in Pseudomonas aeruginosa do not translate to in vivo failure in efficacy or emergence of resistance to meropenem, imipenem, or cefepime Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy 2004 American Society for Microbiology Washington, DC
37. Tam VH, Schilling AN, Melnick DA, and Coyle EA Comparison of beta-lactams in counter-selecting resistance of Pseudomonas aeruginosa Diagn Microbiol Infect Dis. 52 2005 145 151
38. Kuti JL, Horowitz S, and Nightingale CH Evaluation of pharmacodynamic target attainment between healthy subject and patient data using Monte Carlo simulation Pharmacotherapy. 25 2005 935 941
39. Garg AX, Papaioannou A, and Ferko N Estimating the prevalence of renal insufficiency in seniors requiring long-term care Kidney Int. 65 2004 649 653
40. Hoste EA, Damen J, and Vanholder RC Assessment of renalfunction in recently admitted critically ill patients with normal serum creatinine Nephrol Dial Transplant. 20 2005 747 753
41. Streit JM, Jones RN, Sader HS, and Fritsche TR Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: Report from the SENTRY Antimicrobial Surveillance Program (North America, 2001) Int J Antimicrob Agents. 24 2004 111 118
42. Friedland I, Gallagher G, King T, and Woods GL Antimicrobial susceptibility patterns in Pseudomonas aeruginosa: Data from a multicenter Intensive Care Unit Surveillance Study (ISS) in the United States J Chemother. 16 2004 437 441